Manufacturers looking to optimise access for their orphan drugs need to navigate a complex environme...
Read moreISPOR Europe 2025 brought together global HTA bodies, payers, industry leaders and patient organisat...
Read more2025 was a pivotal year for market access, marked by the growing convergence between scientific inno...
Read moreEvery payer ultimately asks the same question: “Compared with what?” This single question shapes...
Read moreObjectives: In March 2025, NICE adopted new HST routing criteria for evaluating technolo...
Read moreSurrogate Endpoints in HTA Decision-Making The need to stay ahead of competitors and offset losses f...
Read moreNICE’s Highly Specialised Technologies (HST) Programme offers a vital route for bringing ultra-rar...
Read moreAdvanced Therapy Medicinal Products (ATMPs) are offering transformative, and often life-saving, trea...
Read moreAdvanced Therapy Medicinal Products (ATMPs) are leading in healthcare innovation, providing potentia...
Read moreThe pricing benchmark has shifted faster than systems have adapted. In the UK, prices for one-time t...
Read more